Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Leoclan CoTSE:7681 66 EBITDA Margin % is 3.35% as of Mar. 2026, which is 46% above its 10-year median of 2.30. GuruFocus rates TSE:7681 with a GF Score™ of 66/100 and a GF Value™ of 円1,290.91 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 118 Medical Distribution companies, Leoclan Co ranks worse than 75.42% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Leoclan Co's EBITDA for the
six
months ended in Mar. 2026 was 円814 Mil. Leoclan Co's Revenue for the
six
months ended in Mar. 2026 was 円24,281 Mil. Therefore, Leoclan Co's EBITDA margin for the quarter that ended in Mar. 2026 was 3.35%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Leoclan Co EBITDA Margin % Related Terms
Leoclan Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Leoclan Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7681 vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Leoclan Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Leoclan Co EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Leoclan Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Leoclan Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Leoclan Co (TSE:7681) has a EBITDA Margin % of 3.35% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Leoclan Co and its competitors. This is 46% above median its historical median of 2.30. Over the past decade, Leoclan Co's EBITDA Margin % has ranged from 1.37 to 3.64. According to the industry distribution chart, Leoclan Co ranks #89 out of 118 companies in the Medical Distribution industry, placing it in the top 75.4%.
Is Leoclan Co's EBITDA Margin % too high?
Leoclan Co's current EBITDA Margin % of 3.35% is 46% above median its 10-year median of 2.30. Over the past 10 years, this metric has ranged from a low of 1.37 to a high of 3.64. The Medical Distribution industry median EBITDA Margin % is 4.16. Leoclan Co's value of 3.35% is 19.4% below this industry median. Based on the distribution chart, Leoclan Co ranks #89 out of 118 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Leoclan Co has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Leoclan Co's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Leoclan Co ranks #89 out of 118 companies for EBITDA Margin %. This places Leoclan Co in the lower half of its industry. The industry median EBITDA Margin % is 4.16. Leoclan Co's value of 3.35% is 19.4% below this benchmark. Historically, Leoclan Co's own EBITDA Margin % has ranged from 1.37 to 3.64 over the past decade. While the company's 10-year median is 2.30 vs. the industry median of 4.16, Leoclan Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.16, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Leoclan Co's current EBITDA Margin % of 3.35% is 19.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Leoclan Co and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Leoclan Co's current EBITDA Margin % is 3.35%, which is 46% above median its own 10-year median of 2.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Leoclan Co stock overvalued right now?
Based on GuruFocus' analysis, Leoclan Co (TSE:7681) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,290.91, compared to a current price of 円955.00 — trading 26% below its estimated fair value. The current EBITDA Margin % is 3.35%, which is 46% above median its 10-year median of 2.30 and 19.4% below the Medical Distribution industry median of 4.16. Leoclan Co's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Leoclan Co (TSE:7681), the current EBITDA Margin % is 3.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Leoclan Co (TSE:7681) Overvalued in 2026?
Based on GuruFocus' analysis, Leoclan Co stock appears to be undervalued.
The current stock price of 円955.00 is trading 26% below its estimated GF Value™ of 円1,290.91.
GuruFocus considers Leoclan Co to be Modestly Undervalued.
Key valuation signals for TSE:7681:
EBITDA Margin %: 3.35% (46% above median its 10-year median of 2.30)
GF Value™: 円1,290.91 vs. price of 円955.00 (26% below fair value)
Industry Position: 19.4% below the Medical Distribution median (#89 of 118)
No single metric tells the full story. See the TSE:7681 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7681 has been successfully added to your 
